… Aerosolized tobramycin has been extensively used in cystic fibrosis … Aerosolized tobramycin
doses ranging from 80 mg twice or three … Tobramycin, nebulized at 600 mg three times daily, …

… In summary, the safety profile of TIP was comparable with the currently approved formulation
of tobramycin, TIS, with the exception of cough, dysphonia and dysgeusia. Patient-reported …

… tobramycin dry powder efficacy in cystic fibrosis) compared TIP with placebo. EAGER
Citation30 (Establish a new gold standard efficacy and safety with tobramycin in cystic fibrosis) …

… tobramycin administration, 22 patients with cystic fibrosis were monitored while receiving
inhaled tobramycin … the end of the 12th week of administration of tobramycin aerosol. Sputum F! …

… Tobramycin is commonly used to treat respiratory tract infections in … cystic fibrosis. We
designed a study to determine the pharmacokinetics and safety of once-daily dosing of tobramycin …

… with cystic fibrosis (CF). This trial was designed to investigate the efficacy and safety of a
highly concentrated (300mg/4mL) tobramycin … a 4-week treatment with tobramycin or placebo …

… The aim of this study was to assess the safety of tobramycin solution for inhalation (TOBI®-TSI)
administered twice daily for 2 months/course concurrently to intravenous (IV) tobramycin …

… that meropenem in combination with tobramycin is as useful for treatment of P. aeruginosa
infection in cystic fibrosis patients as ceftazidime with tobramycin. In addition to its clinical …

… Long-term safety and efficacy of tobramycin inhalation powder in cystic fibrosis patients
with P. aeruginosa: the edit trial and its two open-label extension studies. 27th North American …

… safety of tobramycin inhalation powder (TIP), a novel dry-powder formulation designed to
deliver a high payload of tobramycin … 300 mg dose of tobramycin solution for inhalation (TSI) as …